

OPENLAB VERIFIED · Report identity and source-transcribed quantity. Compound purity and analytical events retain their separate source scopes.

HALO

Lab record

Batch	Laboratory	Report	Analysed
OL2209	Janoshik Analytical	28939	18 April 2023

Powered by EvidenceOS, connecting this Olympus Labs UK product and batch to its laboratory results and source evidence.

Halo · Concentration

34.70 mg

Reported sample; the laboratory gives mg without a per-capsule denominator.

Janoshik report 28939 · OL2209

Halo · Purity

>90%

Compound raw material

Olympus Labs UK · compound purity statement

REPORTED

Compound identity

Halodrol

REPORTED

Reported quantity

34.70 mg

REPORTED

Compound purity

>90%

REPORTED

Laboratory source

Janoshik

REPORTED

Batch connection

OL2209

REPORTED

Sample receipt

2023-04-14

The batch report and supporting compound analyses retain their separate dates and source identities. Compound raw-material purity is a supporting observation; production stage is unspecified.

HALO · reading this record

Batch OL2209 · Report 28939 · 18 April 2023

Reading Halo's purity and quantity results

Olympus Labs UK reports >90% chromatographic purity for the Halodrol raw material. This is a qualified compound-purity statement: it reports a lower bound, not an exact percentage or a result for the finished capsule.

Janoshik report 28939 separately identifies Halodrol and reports 34.70 mg in the tested sample from batch OL2209. Purity and quantity describe different measurements; neither value replaces the other, and the percentage alone does not establish a pass or fail against a universal purity threshold.

The unassigned chromatogram row showing 0.00 is not a zero-dose finding. The signed report's 34.70 mg result remains the quantity observation.

Evidence used for this explanation

HALO · publisher purity statement

a2f41150bdd0d7bd0c84b38e1b55b724bdc18f5b2573000ba71ec16bebcd0e97

Janoshik report 28939

126bb8007f2bdee2f757061f106706f7b83fa829bd0b4a0aac3c705546a6437d

HALO · PDA Ch5 227 nm · 2023-04-14

a863cd399922849531c0cb849892c2f386e393fdb49cd97ccaea0917e79862a1



Compound analysis

Halodrol · LC/MS chromatogram · 2022-08-16

LC/MS 16 August 2022 DAD1 B, 220 nm

LC/MS Report

File D:\CHEM32\DATA\202208\20220816-KEHU-1 2022-08-16 16-58-11\HA-20220816-LCMS.D
Injection Date : 16-Aug-22, 18:21:57 Tgt Mass (EZ) :
Sample Name : Location : P1-F-04
Acq. Operator : Inj : 1
Spec. Reported : MS Integration Inj Volume : 10 ul
Acq. Method : D:\CHEM32\DATA\202208\20220816-KEHU-1 2022-08-16 16-58-11\401-CZ-RK.M
Analysis Method : C:\Chem32\1\METHODS\401-GP50-KEHU.M
Sample Info :
Method Info : Instrument : Agilent 1200-6110 MS
Mobile Phase : A=0.1%TFA in water, B=Acetonitrile
Gradient : 5-95% B in 4 min, 95%B in isocratic for 3min
Flow Rate : 0.6 mL/min
Column : XDB-C18 2.1*50mm, 3.5um
Column temperature : 35°C



Integration Results for DAD1 B, Sig=220,8 Ref=off


RetTim	Width	Area	Height	Area%
12.32	0.10	24.38	3.61	0.56
12.91	0.13	1397.22	153.85	32.14
13.09	0.17	2536.43	196.91	58.34
13.34	0.09	50.36	7.04	1.16
13.81	0.05	11.80	4.21	0.27
13.94	0.09	54.75	8.48	1.26
14.04	0.13	127.23	13.60	2.93
18.46	0.21	145.50	8.37	3.35

Compound analysis

Halodrol · mass spectrum · 2022-08-16

LC/MS 16 August 2022 Original source spectrum

LC/MS Report



Instrument 1 8/17/2022 10:23:51 AM

Page 2 of 3

Original analytical page · Supporting compound evidence


Compound analysis

Halodrol · mass spectrum · 2022-08-16

LC/MS 16 August 2022 Original source spectrum

LC/MS Report

Ret. Time: 14.21



Original analytical page · Supporting compound evidence

Sample analysis

HALO · PDA Ch5 227 nm · 2023-04-14

Chromatography 14 April 2023 PDA Ch5 227 nm




Analysis Report

<Sample Information>

Sample Name : 1275-12
Method Filename : Raws - blind common anabolic steroid and aromatase inhibitors screening.lcm
Vial # : 3-10 Sample Type : Unknown
Injection Volume : 0.5 uL
Date Acquired : 14/04/2023 11:10:51 Acquired by : Janoshik s.r.o.
Date Processed : 14/04/2023 11:15:26 Processed by : Janoshik s.r.o.

<Chromatogram>

mAU



<Peak Table>

PDA Ch5 227nm

Peak#	Ret. Time	Concentration	Unit	Name
1	1.228	0.00		
Total		0.00		

info@janoshik.com

Original analytical page · Report 28939

Sources and record edition

TEST REPORT



E-mail: info@janoshik.com
Web: www.janoshik.com

Task Number

#28939

Testing ordered >

31 MAR '23

Sample received >

14 APR '23

Client

support@olympuslabs.uk

Sample

HALO 33.3MG

Manufacturer

Olympus Labs UK

Batch

OL2209

Sample description >

Pictures not included.

Tests requested >

Qualitative and quantitative analysis of non-AAS sample.

Results >

Halodrol	34.70 mg

Comments >

Analysis conducted >

18 APR 2023

Signature >



Verify this test at www.janoshik.com/verify/ with the following unique key

N9ELBRMPAJ27

Laboratory dates

Sample received: 14 April 2023

Analysed: 18 April 2023

Janoshik · 28939

[View source](#)

156cc9bca11e7b9d92a026de420789050fa587bed66394f9d240e72f2aca717a

Halodrol · LC/MS chromatogram · 2022-08-16

Source image included in this edition.

3751698705cc315c9e4eedf47aa9351bd18bba9a9fa4dfa01dda425a0275ff78

Halodrol · mass spectrum · 2022-08-16

Source image included in this edition.

a091fbc191c11b2f8748dc88099a1f401a0b8a47c94b7ed28c7615012abdaed1

Halodrol · mass spectrum · 2022-08-16

Source image included in this edition.

fe7e61ca1dd35989e1943931b8679042db6e972913578139aff7dad7fbebbaed

Janoshik report 28939

[View source](#)

126bb8007f2bdee2f757061f106706f7b83fa829bd0b4a0aac3c705546a6437d

HALO · publisher purity statement

[View source](#)

a2f41150bdd0d7bd0c84b38e1b55b724bdc18f5b2573000ba71ec16bebcd0e97

HALO · PDA Ch5 227 nm · 2023-04-14

[View source](#)

a863cd399922849531c0cb849892c2f386e393fdb49cd97ccaea091e79862a
1

Edition

openlab.v2.b6e333f894136844

Record digest:

bfcc1421aca1f668766b62dea5094bc3095ea04d99bade22b12c660d008b52f6